中国现代医生
中國現代醫生
중국현대의생
CHINA MODERN DOCTOR
2015年
2期
76-78
,共3页
缺血性脑卒中%强化降脂%白介素-6%白介素-8%白介素-10
缺血性腦卒中%彊化降脂%白介素-6%白介素-8%白介素-10
결혈성뇌졸중%강화강지%백개소-6%백개소-8%백개소-10
Cerebral arterial thrombosis%Intensive lipid-lowering%Interleukin-6%Interleukin-8%Interleukin-10
目的：探讨强化降脂对缺血性脑卒中患者血清白介素-6、8和10水平的影响及疗效观察。方法将88例缺血性脑卒中患者随机分为强化组﹙n=44)和普通组﹙n=44)。两组均予以降颅内压、控制血压和血糖、抗血小板聚集及营养脑细胞等治疗。普通组加用阿托伐他汀片口服,20 mg/次,1次/d；强化组加用阿托伐他汀片口服,40 mg/次,1次/d,两组连用4周。观察并记录两组治疗前和治疗2周和4周后血清IL-6、8和10水平变化,并比较其疗效及不良反应。结果治疗2周和4周后,两组血清IL-6、8水平较前明显下降,IL-10水平较前明显上升﹙P<0.05或P<0.01),且强化组下降或上升值明显大于普通组﹙P<0.05)；同时治疗4周后强化组临床总有效率明显高于普通组﹙χ2=5.09,P<0.05),两组治疗中未发生明显药物不良反应。结论阿托伐他汀强化降脂治疗缺血性脑卒中疗效确切,安全性较好,与其能降低血清IL-6、8水平和上调血清IL-10水平及纠正血清炎症因子网络紊乱密切相关。
目的：探討彊化降脂對缺血性腦卒中患者血清白介素-6、8和10水平的影響及療效觀察。方法將88例缺血性腦卒中患者隨機分為彊化組﹙n=44)和普通組﹙n=44)。兩組均予以降顱內壓、控製血壓和血糖、抗血小闆聚集及營養腦細胞等治療。普通組加用阿託伐他汀片口服,20 mg/次,1次/d；彊化組加用阿託伐他汀片口服,40 mg/次,1次/d,兩組連用4週。觀察併記錄兩組治療前和治療2週和4週後血清IL-6、8和10水平變化,併比較其療效及不良反應。結果治療2週和4週後,兩組血清IL-6、8水平較前明顯下降,IL-10水平較前明顯上升﹙P<0.05或P<0.01),且彊化組下降或上升值明顯大于普通組﹙P<0.05)；同時治療4週後彊化組臨床總有效率明顯高于普通組﹙χ2=5.09,P<0.05),兩組治療中未髮生明顯藥物不良反應。結論阿託伐他汀彊化降脂治療缺血性腦卒中療效確切,安全性較好,與其能降低血清IL-6、8水平和上調血清IL-10水平及糾正血清炎癥因子網絡紊亂密切相關。
목적：탐토강화강지대결혈성뇌졸중환자혈청백개소-6、8화10수평적영향급료효관찰。방법장88례결혈성뇌졸중환자수궤분위강화조﹙n=44)화보통조﹙n=44)。량조균여이강로내압、공제혈압화혈당、항혈소판취집급영양뇌세포등치료。보통조가용아탁벌타정편구복,20 mg/차,1차/d；강화조가용아탁벌타정편구복,40 mg/차,1차/d,량조련용4주。관찰병기록량조치료전화치료2주화4주후혈청IL-6、8화10수평변화,병비교기료효급불량반응。결과치료2주화4주후,량조혈청IL-6、8수평교전명현하강,IL-10수평교전명현상승﹙P<0.05혹P<0.01),차강화조하강혹상승치명현대우보통조﹙P<0.05)；동시치료4주후강화조림상총유효솔명현고우보통조﹙χ2=5.09,P<0.05),량조치료중미발생명현약물불량반응。결론아탁벌타정강화강지치료결혈성뇌졸중료효학절,안전성교호,여기능강저혈청IL-6、8수평화상조혈청IL-10수평급규정혈청염증인자망락문란밀절상관。
Objective To discuss the influence and curative effect of intensive lipid-lowering on serum Interleukin-6, 8 and 10﹙IL-6, 8 and 10) levels of patients with cerebral arterial thrombosis. Methods A total of 88 cases of patients with cerebral arterial thrombosis were selected and divided into intensive group ﹙n=44) and ordinary group ﹙n=44) at random. The patients in two groups were promptly given routine lowering intracranial pressure, control of blood pres-sure and blood sugar, anti-platelet aggregation, brain cells nutrition and other medical treatment. The patients in ordi-nary group were additionally given Atorvastatin tablets through the mouth, 20 mg per time, once a day, and the patients in intensive group were additionally given Atorvastatin tablets through the mouth, 40 mg per time, once a day for 4 weeks. The changes of serum IL-6, 8 and 10 levels of patients in two groups before and 2 or 4 weeks after medical treatment were observed and recorded, and the clinical curative effect and drug adverse reaction﹙DAR) were compared as well. Results After 2 or 4 weeks’medical treatment, the serum IL-6 and 8 levels of patients in two groups obviously declined than before, while the IL-10 levels obviously rose than before ﹙P<0.05 or P<0.01), and the declining or rising rates of patients in intensive group were much higher than those in ordinary group ﹙P<0.05). Meanwhile, the total clinical efficiency of patients in intensive group was much higher than that in ordinary group after 2 or 4 weeks’medi-cal treatment ﹙χ2=5.09, P<0.05). No obvious DAR appeared on patients in two groups during the medical treatment. Conclusion Atorvastatin intensive lipid-lowering has reliable curative effect on cerebral arterial thrombosis with high security, whose mechanism of action has close effect on reducing the serum IL-6 and 8 levels, raising serum IL-10 level, adjusting the serum inflammatory cytokines network disorder.
